<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072709</url>
  </required_header>
  <id_info>
    <org_study_id>CTCH346A2211</org_study_id>
    <nct_id>NCT00072709</nct_id>
  </id_info>
  <brief_title>Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Stratified, Parallel-Group, Multicenter, Dose-Ranging Study Evaluating Four Oral Doses of TCH346 (1.0, 2.5, 7.5 and 15 mg) Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a global multicenter study designed to evaluate the safety and clinical effects of 4
      oral doses of TCH346 (1.0, 2.5, 7.5, and 15 mg) compared to placebo in patients with mild or
      mild to moderate stages of ALS. The study consists of 3 phases: screening (up to 2 weeks),
      run-in (16 weeks), and a double-blind treatment phase of variable duration (at least 24
      weeks).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of functional decline as defined by the ALS Functional Rating Scale-Revised</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome measures including pulmonary function and manual muscle strength assessments (every visit except screening)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive evaluation in a subset of patients(every visit except screening)</measure>
  </secondary_outcome>
  <enrollment type="Actual">551</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCH346</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  clinical diagnosis of laboratory-supported probable, probable, or definite ALS;

          -  sporadic or familial ALS;

          -  ALS symptom onset for no more than 3 yrs at study entry;

          -  FVC equal to or more than 70%;

          -  patients who are either riluzole naive or patients who are receiving concomitant
             treatment with riluzole at a stable dose of riluzole (50 mg bid) at study start.

        Exclusion criteria:

          -  Known or suspected chronic infectious disease including HIV, hepatitis B, or hepatitis
             C.

          -  Clinically significant ECG abnormalities.

          -  Known hypersensitivity to study drug or related drugs (e.g. selegiline, MAO-A and B
             inhibitors, or tricyclic antidepressants).

          -  Patients treated with potent inhibitors of CYP1A2 or CYP3A4 (a list of such inhibitors
             will be provided to the investigator).

          -  Treatment with MAO-A and B inhibitors (including selegiline) within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis USA</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Belgium</name>
      <address>
        <city>Vilvoorde</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis CANADA</name>
      <address>
        <city>Dorval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis France</name>
      <address>
        <city>Rueil-Malmaison</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Germany</name>
      <address>
        <city>Nuernberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Italy</name>
      <address>
        <city>Saronno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Netherlands</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Switzerland</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis UK</name>
      <address>
        <city>Frimley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2003</study_first_submitted>
  <study_first_submitted_qc>November 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2003</study_first_posted>
  <last_update_submitted>November 22, 2011</last_update_submitted>
  <last_update_submitted_qc>November 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Lou Gehrig's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

